'
The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
Related Resources for this page:
- Tumor Types
- Clinical Trials
- Cancer Biomarkers
- Breast Cancer
- Receptor-Mediated Endocytosis
- Genome instability and mutation
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- HER2+ breast cancer
- HER2 dimerization
- Research HDIs
- Slide decks and videos
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Receptor-Mediated Endocytosis
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- VEGF in lung cancer
- Prevalence of VEGF
- VEGF and prognosis
- Malignant pleural effusion
- Survival
- Summary
- Evidence of VEGF expression
- VEGF and disease progression
- Breast Cancer
- Future Directions
- Antibody-Drug conjugates
- HER Signaling
- Receptor-Mediated Endocytosis
- Anti-HER3/EGFR MAb (MEHD7945A)
- Anti-PDL1 (MPDL3280A)
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- Emerging therapeutic options
- Emerging therapeutic options
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Apoptosis
- MAPK Signaling
- PI3K/Akt/mTOR Signaling
- Anti-HER3/EGFR MAb (MEHD7945A)
- MEK Inhibitor (GDC-0973)
- PI3K Inhibitor (GDC-0941)
- Glossary
- Apoptosis
- The Bcl-2 family
- Apoptotic pathways
- Reactivating apoptosis
- Resisting apoptosis
- Useful resources
- Emerging therapeutic options
- Emerging therapeutic options
- Emerging therapeutic options
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- Gastric Cancer
- Melanoma
- Traditional Monoclonal Antibodies
- Angiogenic Signaling
- B-cell Surface Proteins
- HER Signaling
- Parsatuzumab (Anti-EGFL7)
- Anti-HER3/EGFR MAb (MEHD7945A)
- Anti-PDL1 (MPDL3280A)
- Direct cell death
- Emerging therapeutic options
- Emerging therapeutic options
- Emerging therapeutic options
- Inhibition of HER2 dimerization
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Glossary
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- Gastric Cancer
- Melanoma
- Antibody-Drug conjugates
Share
Click here to view a larger version of this image
MetMAb
Blocking HGF/SF binding may prevent Met dimerization and activation, ultimately inhibiting downstream signaling events.1,2
Onartuzumab (MetMAb) is a monovalent (one-armed), monoclonal antibody designed to bind to Met and inhibit HGF/SF binding.3,4 Traditional bivalent antibodies to Met potentially activate, rather than inhibit, Met signaling by inducing Met dimerization.5-6 In contrast, the monovalent design of Onartuzumab (MetMAb) inhibits HGF/SF binding without inducing Met dimerization.4 Onartuzumab (MetMAb) has demonstrated antitumor activity in preclinical analyses.4
- MetMAb was specifically designed as a monovalent antibody to avoid agonistic activity that may occur when a bivalent antibody binds two Met molecules.4,6

- MetMAb binds to the Sema domain of Met, an extracellular region essential for binding its ligand, HGF/SF.3,4

- MetMAb inhibits HGF/SF from binding to Met, thereby blocking ligand-induced Met dimerization and activation of the intracellular kinase domain.4

- Blockade of Met activation inhibits its downstream pathways, preventing cancer cell growth, survival, and metastasis.4

References:
- 1.
- Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915-925. PMID: 14685170
- 2.
- Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol. 2005;7:436-451. PMID: 16212809
- 3.
- Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004;6:75-84. PMID: 15261143
- 4.
- Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12:6144-6152. PMID: 17062691
- 5.
- Ohashi K, Marion PL, Nakai H, et al. Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med. 2000;6:327-331. PMID: 10700236
- 6.
- Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci. 1998;111:237-247. PMID: 9405310